Get the Stockscreener App
3.815
1.60%
0.055
Maxcyte Inc stock is traded at $3.815, with a volume of 173.16K.
It is up +1.60% in the last 24 hours and up +4.09% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$3.76
Open:
$3.73
24h Volume:
173.16K
Relative Volume:
0.55
Market Cap:
$401.97M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-11.92
EPS:
-0.32
Net Cash Flow:
$-25.39M
1W Performance:
+7.00%
1M Performance:
+4.09%
6M Performance:
+1.33%
1Y Performance:
+11.70%
1-Day Range:
$3.70
$3.87
1-Week Range:
$3.52
$3.87
52-Week Range:
$3.15
$5.545
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
MaxCyte Expands Stock Capital with New Issuance - TipRanks
MaxCyte (LON:MXCT) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
MaxCyte to Participate in Two Upcoming Investor Conferences - StockTitan
MaxCyte to Join Key Investor Conferences in November - TipRanks
MaxCyte’s Insider Stock Activity in Focus - TipRanks
MaxCyte director Johnston sells $11,166 in stock - Investing.com
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company - Yahoo Finance
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - MarketBeat
Grant of Options and Restricted Stock Units - ShareCast
MaxCyte Awards Stock Options to Boost Growth - TipRanks
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
MaxCyte Appoints Cynthia Collins to its Board of Directors - ForexTV.com
MaxCyte Strengthens Board with Cynthia Collins Appointment - TipRanks
MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer - Head Topics
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - ForexTV.com
MaxCyte to Unveil Q3 2024 Financial Results - TipRanks
People on the Move: Ali Soleymannezhad, Chief Commercial Officer, MaxCyte - BioBuzz
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - citybiz
MaxCyte appoints new chief commercial officer - ShareCast
MaxCyte appoints Soleymannezhad as CCO - TipRanks
MaxCyte Names New CCO for Market Expansion - TipRanks
MaxCyte upgraded to Buy from Hold at Deutsche Bank - TipRanks
Marshall Wace LLP Acquires New Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up (NASDAQ:MXCT) - Seeking Alpha
Stan Erck Sells 47,689 Shares of MaxCyte, Inc. (LON:MXCT) Stock - MarketBeat
MaxCyte, Inc. (LON:MXCT) Insider Sells £185,033.32 in Stock - Defense World
MaxCyte Director Executes Stock Options Sale - TipRanks
MaxCyte director Stanley Erck sells shares worth over $178k - Investing.com
MaxCyte director Stanley Erck sells shares worth over $178k By Investing.com - Investing.com Australia
MaxCyte, Inc. (NASDAQ:MXCT) Director Sells $80,161.97 in Stock - MarketBeat
Overcome the limitations of conventional transfection with MaxCyte Electroporation - LabRoots
MaxCyte Director Executes Stock Options and Sells Shares - TipRanks
MaxCyte Expands Share Capital, Fuels Cell Therapy Growth - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - Defense World
Maxcyte director Johnston sells shares worth over $11,000 By Investing.com - Investing.com Australia
Maxcyte director Johnston sells shares worth over $11,000 - Investing.com
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
MaxCyte (LON:MXCT) Stock Price Passes Below 50 Day Moving Average of $325.72 - MarketBeat
MaxCyte (LON:MXCT) Shares Cross Below 50 Day Moving Average of $325.72 - Defense World
MaxCyte shares retain buy rating on strong cell therapy platform By Investing.com - Investing.com Australia
MaxCyte shares retain buy rating on strong cell therapy platform - Investing.com
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth - Yahoo Finance
Massachusetts Financial Services Co. MA Has $1.96 Million Stake in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases - MSN
Massachusetts Financial Services Co. MA Cuts Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BlackRock Ups Stake in MaxCyte to 9.75% - TipRanks
Rx Rundown: MaxCyte, Roche, and more - MM+M Online
MaxCyte Signs Strategic Platform License With Kamau Therapeutics To Accelerate the Development of Cell Therapies for Genetic Diseases - Technology Networks
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maxcyte Inc Stock (MXCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Johnston John Joseph | Director |
Oct 28 '24 |
Sale |
3.72 |
3,000 |
11,166 |
141,950 |
| Erck Stanley C | Director |
Oct 01 '24 |
Option Exercise |
0.04 |
26,082 |
1,043 |
295,200 |
| Erck Stanley C | Director |
Oct 02 '24 |
Option Exercise |
0.04 |
21,607 |
864 |
290,725 |
| Erck Stanley C | Director |
Oct 01 '24 |
Sale |
3.78 |
26,082 |
98,590 |
269,118 |
| Erck Stanley C | Director |
Oct 02 '24 |
Sale |
3.71 |
21,607 |
80,162 |
269,118 |
| Johnston John Joseph | Director |
Sep 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,778 |
144,950 |
| Johnston John Joseph | Director |
Sep 26 '24 |
Sale |
3.82 |
3,000 |
11,460 |
141,950 |
0.55%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):